Journal of Law, Medicine and Ethics 41 (3):654-664 (2013)

Abstract
Prescribing drugs for uses that the FDA has not approved — off-label drug use — can sometimes be justified but is typically not supported by substantial evidence of effectiveness. At the root of inappropriate off-label drug use lie perverse incentives for pharmaceutical firms and flawed oversight of prescribing physicians. Typical reform proposals such as increased sanctions for manufacturers might reduce the incidence of unjustified off-label use, but they do not remove the source of the problem. Public policy should address the cause and control the practice. To manage inappropriate off-label drug use, off-label prescriptions must be tracked in order to monitor the risks and benefits and the manufacturers’ conduct. Even more important, reimbursement rules should be changed so that manufacturers cannot profit from off-label sales. When off-label sales pass a critical threshold, manufacturers should also be required to pay for independent testing of the safety and effectiveness of off-label drug uses and for the FDA to review the evidence. Manufacturers should also finance, under FDA supervision, programs designed to warn physicians and the public about the risks of off-label drug use
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1111/jlme.12075
Options
Edit this record
Mark as duplicate
Export citation
Find it on Scholar
Request removal from index
Revision history

Download options

PhilArchive copy


Upload a copy of this paper     Check publisher's policy     Papers currently archived: 64,178
Through your library

References found in this work BETA

View all 17 references / Add more references

Citations of this work BETA

Five Un‐Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.

View all 9 citations / Add more citations

Similar books and articles

Speaking Off Label.Stephen R. Latham - 2010 - Hastings Center Report 40 (6):9-10.
Five Un‐Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
Drug Labeling: FDA Requires New Label for Antibiotics To Prevent Overuse.Devesh Tiwary - 2003 - Journal of Law, Medicine and Ethics 31 (3):458-460.
生命的哲学 ‐后基因时代药物筛选策略与传统中药学理论.Xiao Ming Wang - 2008 - Proceedings of the Xxii World Congress of Philosophy 44:139-142.
Toward Drug Control: Exclusion and Buyer Licensing. [REVIEW]Jim Leitzel - 2013 - Criminal Law and Philosophy 7 (1):99-119.
Thoughts About the Autism Label: A Parental View.Charlotte Moore - 2008 - Journal of Philosophy of Education 42 (3-4):493-498.

Analytics

Added to PP index
2013-10-02

Total views
20 ( #540,600 of 2,455,063 )

Recent downloads (6 months)
1 ( #449,153 of 2,455,063 )

How can I increase my downloads?

Downloads

My notes